VEGFA and familial pancreatic carcinoma: Combination therapy of the recombinant humanized anti-VEGF monoclonal antibody bevacizumab and gemcitabine in a Phase 2 clinical trial yielded a partial response for 21% of patients and disease stabilization in 46% of patients diagnosed with advanced pancreatic cancer [166], with a significantly decreased reciprocal of doubling time [167] reported in another study (NCT00460174).